학술논문
Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy
Document Type
Academic Journal
Author
Masquelier, Bernard; Taieb, Audrey; Reigadas, Sandrine; Marchou, Bruno; Cheneau, Christine; Spire, Bruno; Charpentier, Charlotte; Leport, Catherine; Raffi, François; Chêne, Geneviève; Descamps, Diane; Leport, C.; Raffi, F.; Chêne, G.; Salamon, R.; Moatti, J.-P.; Pierret, J.; Spire, B.; Brun-Vézinet, F.; Fleury, H.; Masquelier, B.; Peytavin, G.; Garraffo, R.; Costagliola, D.; Dellamonica, P.; Katlama, C.; Meyer, L.; Salmon, D.; Sobel, A.; Cuzin, L.; Dupon, M.; Duval, X.; Le Moing, V.; Marchou, B.; May, T.; Morlat, P.; Rabaud, C.; Waldner-Combernoux, A.; Reboud, P.; Couffin-Cadiergues, Sandrine; Marchand, Lucie; Bouteloup, V.; Bouhnik, A. D.; Brunet-François, C.; Caron, V.; Carrieri, M. P.; Courcoul, M.; Couturier, F.; Hardel, L.; Iordache, L.; Kurkdji, P.; Martiren, S.; Préau, M.; Protopopescu, C.; Surzyn, J.; Taieb, A.; Villes, V.; Schmit, J. L.; Chennebault, J. M.; Faller, J. P.; Mgy-Bertrand, N.; Hoen, B.; Drobachef; Bouchaud, O.; Dupon, M.; Longy-Boursier; Morlat, P.; Ragnaud, J. M.; Granier, P.; Garré, M.; Verdon, R.; Merrien, D.; Devidas, A.; Sobel, A.; Piroth, L.; Perronne, C.; Froguel, E.; Ceccaldi, J.; Peyramond, D.; Allard, C.; Reynes, J.; May, T.; Raffi, F.; Fuzibet, J. G.; Dellamonica, P.; Arsac, P.; Bouvet, E.; Bricaire, F.; Bergmann, P.; Cabane, J.; Monsonego, J.; Girard, P. M.; Guillevin, L.; Herson, S.; Leport, C.; Meyohas, M. C.; Molina, J. M.; Pialoux, G.; Salmon, D.; Roblot, P.; Jaussaud, R.; Michelet, C.; Lucht, F.; Debord, T.; Rey, D.; De Jaureguiberry, J. P.; Marchou, B.; Bernard, L.
Source
Journal of Antimicrobial Chemotherapy. Jul 01, 2011 66(7):1582-1589
Subject
Language
English
ISSN
0305-7453
Abstract
BACKGROUND: The aim of our study was to determine whether HIV-1 DNA level before antiretroviral therapy (ART) was associated with short- and long-term virological and immunological responses. METHODS: Patients starting first-line protease inhibitor-containing regimens were enrolled in a prospective multicentre cohort in 1998–99. HIV-1 DNA was quantified using real-time PCR at baseline and after 1 year of ART. The association between HIV-1 DNA and virological and immunological responses after 1 and 7 years on ART was studied in multivariate regression models along with other biological and clinical variables. Virological failure (VF) at month 12 (M12) was defined as a plasma HIV-1 RNA >500 copies/mL. Time to death or two plasma HIV-1 RNA >500 copies/mL between M12 and M84 was studied for long-term VF. RESULTS: HIV-1 DNA levels were measured in 148 patients. The median baseline peripheral blood mononuclear cell (PBMC) HIV-1 DNA was 3.7 log10 copies/10 PBMCs. At M12, the median PBMC HIV-1 DNA was 2.99 log10 copies/10 PBMCs. The median decrease in PBMC HIV-1 DNA between M0 and M12 was −0.7 log10 copies/10 PBMCs. Higher baseline PBMC HIV-1 DNA and plasma HIV-1 RNA were independently associated with a higher risk of VF at M12. Only the baseline plasma HIV-1 RNA was independently associated with long-term virological response. The baseline CD4 cell count was the only parameter associated with short- and long-term immunological responses. CONCLUSIONS: HIV-1 DNA impacted the virological response in our cohort. Further research is warranted to study the impact of HIV-1 DNA with currently recommended first-line cART.